bluuebunny/crossref_metadata_2025_split huggingface dataset:
P6503Impact of ascending aortic disease categories on the histopathological degenerative changes in relation to aorta dimensions
Authors: Amemiya K , Mousseaux E , Ueda H , Ochiai M , Bruneval P 
Published: October 2019

Abstract

Background
Recently a consensus statement on surgical pathology of the aorta was published to improve pathological assessment of non-inflammatory aortic diseases.

Purpose
We used data of the ascending aorta surgical specimens for aneurysm or dissection to better understand the relationship between the histological medial degenerative changes (MDC) and aortic size assessed by computed tomography.

Methods
In this retrospective single center study we retrieved 719 ascending aorta surgical specimens from January 2010 until June 2018 and analyzed them according to the consensus statement and scored MDC [elastic fiber fragmentation and/or loss (EFFL), smooth muscle nuclei loss (SMNL), mucoid extracellular matrix accumulation (MEMA); intralamellar (I) or translamellar (T)] and measured medial wall thickness on correlation with imaging data and the status [thoracic aorta aneurysm (TAA), dissection (TAD), bicuspid aortic valve (BAV) or non-BAV].

Results
We analyzed 517 patients with degenerative aortic diseases (mean age, 61 years) whose imaging data were obtained, with BAV in 203 (TAD 4%, TAA 96%) and with non-BAV in 314 (TAD 44%, TAA 56%). In TAA subset, scores of EFFL, SMNL and MEMA-T were lower in BAV than in non-BAV (p<0.01). Maximum aortic diameters averaged 50 mm in TAD and 53 mm in TAA. In relation to the aortic diameter, the scores of EFFL, SMNL and MEMA-T were more important in non-BAV subset than in BAV, and in TAD subset than in TAA particularly at the small aortic diameters (<50mm) (Figure). Independent predictors of aortic dissection included thicker medial wall (odds ratio [OR], 6.5; 95% confidence interval [CI], 2.6 to 17.6; p<0.0001) and greater SMNL (OR, 1.2; 95% CI, 1.1 to 1.3; p=0.003).

Conclusions
Non-BAV aortas were associated with higher scores of MDC than BAV aortas. Advanced MDC was correlated with increased aortic diameter in the ascending aortic diseases. However, in even smaller aortic diameters, MDC in patients with TAD was important.
P6505Urinary desmosine, an elastin-specific degradation product is associated with maximum aortic root size and aortic z-scores in patients with bicuspid aortic valve
Authors: Iskandar Z , Huang J T J , Mordi I , Miller L D , Chin C , Goudie D , McWilliam C , Berg J , Neagoie A , Lang C C , Choy A M 
Published: October 2019

Abstract

Background
Bicuspid aortic valve (BAV) is the commonest congenital cardiac abnormality affecting up to 2% of the general population. BAV is highly diverse in phenotype however a common feature is its inherent risk of morbidity and mortality from aortic root dilatation and dissection. Aortic dilatation involves elastin degradation and desmosine is an amino acid cross-link that is released into the bloodstream and urine following elastin degradation. It is known from an earlier pilot study (DESMA) of desmosine in Marfan Syndrome (MFS) patients that plasma desmosine among patients with MFS is significantly elevated and correlates with aortic size however whether this same observation is seen in other forms of inherited aortopathies such as BAV is unclear.

Objectives
1. To investigate whether patients with BAV have higher elastin degradation as indicated by plasma desmosine and urinary desmosine levels.
2. To explore the relationship between plasma and urinary desmosine levels with aortic root size in patients with BAV.

Methods
We measured urinary (ng/mg creatinine) and plasma desmosine (ng/mL) in 20 patients with BAV and healthy control subjects using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Aortic root size and corresponding Z-scores were measured on echocardiogram. Correlation was analysed with Spearman's rank test.

Results
The patients with BAV were predominantly male (n=15, 75%) with a mean age of 50.5 years ± 17.6 [SD]. All the BAV patients had normal LV systolic function and none had prior aortic root surgery or were current smokers. Nine BAV patients had treated hypertension. Compared to controls, both plasma desmosine (0.30±0.10 vs 0.26±0.075 ng/mL, p=0.01) and urinary desmosine (15.9±4.6 vs 7.2±2.8 ng/mg creatinine, p<0.001) were significantly elevated in patients with BAV. Urinary and plasma desmosine (Figure 1) were also significantly correlated (r=0.55, p=0.01). There was a significant association between urinary desmosine and maximal aortic root size and Z-scores in the BAV cohort (Figure 2) compared to controls (p=0.02), however this was not seen with plasma desmosine.

Conclusions
Urinary and plasma desmosine levels are significantly higher in patients with BAV compared to controls. Urinary desmosine is also significantly associated with maximal aortic root size, reflecting higher elastin degradation. This suggests a potential use of desmosine as a biomarker to monitor disease progression in patients with BAV.

Acknowledgement/Funding
Anonymous Trust
P6507ST2L and sST2: relationship in the carotid plaque - a study on 76 cases underwent endarterectomy
Authors: Ciccone M M , Cecere A , Bellino M C , Agea A , Zito A , Cortese F , Santoro A , Marzullo A , Scicchitano P 
Published: October 2019

Abstract

Background
ST2 receptor (suppression of tumorigenity) has been described as receptor for the interleukin 33 (IL-33), a member of the IL-1 family of cytokines. This receptor is associated in various way to coronary artery disease, all-causes mortality and cardiovascular mortality. It's role in the pathogenesis of atherosclerosis is not well-defined yet.

Purpose
The present study was designed to assess the relationship between serum level of sST2, a decoy receptor, and immunohistochemicalespression of ST2L in atherosclerotic plaques of formalin fixed paraffin-embedded internal carotid arteries of patients underwent endarterectomy, accepted the predictive value of ST2 in atherosclerosis.

Methods
The study involved 76 cases (31 symptomatic= 41%, 45 asymptomatic= 59%), age range from 47 to 86 years old, underwent endarterectomy for the treatment of internal carotid stenosis in our vascular surgery of polyclinic, all procedures performed by the same physician. Patients were divided into three groups, depending on the presence of ST2Ltransmembrane receptor on the carotid plaque after immunoistochemical evaluation (group low presence of ST2L= 0–1+; moderate presence of ST2= 2+; high presence of ST2= 3+). Serum level of sST2 were defined through the use of an ELISA-kit, specific for ST2 and ready-to-use.

Results
There was a relationship between ST2L and sST2 values: if considering sST2 mean and median value referring to specific subgroup (low, moderate and high), this is lower if the group (i.e. ST2L presence on the atherosclerotic plaque) is higher, and vice-versa. This shows an inverse relationship between this two parameters. Moreover, using Pearson correlation coefficient, all the three sub-group show a strong correlation to the leukocytes value (low=0.658, moderate= 0.434, high= 0.358).

Conclusions
The ST2L immunohistochemical expression was for the first time investigated in a large number of human carotid atherosclerotic plaques. The inverse relationship between ST2L and sST2 supports the pathogenetic hypothesis that ST2L/IL33 axis could drive the mechanism of plaque development and eventually rupture. Correlation with leukocytes provides a further strong evidence confirming inflammatory pathogenesis of atherosclerosis, but most of all leukocytes' high value could be associated to a greater plaque instability.

Acknowledgement/Funding
None
P6517Three-year clinical outcome of patients with abnormal glucose metabolism treated with contemporary drug-eluting stents
Authors: Ploumen E H , Buiten R A , Kok M M , Zocca P , Doggen C J M , Kant G D , Stoel M G , De Man F H A F , Linssen G C M , Doelman C , Sattar N , Von Birgelen C 
Published: October 2019

Abstract

Background/Introduction
Patients with coronary artery disease that have an abnormal glucose metabolism are known to have more extensive and complex atherosclerotic coronary disease. In patients without previously known diabetes, abnormal glucose metabolism was shown to be independently associated with an up to four-fold higher event risk during the first year after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).

Purpose
To examine the 3-year clinical outcome after stenting with contemporary DES in patients with abnormal glucose metabolism, either detected by oral glucose tolerance testing (OGTT) or by glycated haemoglobin A1c (HbA1c) and fasting plasma glucose.

Methods
The present analysis is a local substudy of the BIO-RESORT randomised trial. OGTT and HbA1c with fasting plasma glucose were prospectively assessed in 988 trial participants without previously known diabetes. The main clinical endpoint was target vessel failure, a composite of cardiac death, target vessel-related myocardial infarction or target vessel revascularisation at 3-years.

Results
In one out of three study participants (330/988), abnormal glucose metabolism was detected by either OGTT or HbA1c and fasting plasma glucose. Three-year follow up was available in 99.8% of these patients. The rate of target vessel failure was significantly higher in patients with abnormal glucose metabolism versus normoglycaemic patients (8.8% vs. 5.5%, p=0.044; Figure). This difference was driven by the incidence of periprocedural myocardial infarction that was higher in patients with abnormal glucose metabolism than in patients with normoglycaemia (4.5% vs. 1.4%, p=0.002).
Target vessel failure at 3-years

Conclusion
Abnormal glucose metabolism was associated with a significantly higher risk of target vessel failure at 3-years; this difference was driven by higher rates of periprocedural myocardial infarction.

Acknowledgement/Funding
The present substudy received no additional funding. The BIO-RESORT trial was equally funded by Biotronik, Boston Scientific, and Medtronic.
P6526Short and long-term outcomes of coronary perforation managed by coil embolization: a single-center experience
Authors: Qin Q , Ma J Y , Zhang F , Ge L , Qian J Y , Ge J B 
Published: October 2019

Abstract

Background
Coronary perforation is a serious complication in percutaneous coronary intervention (PCI), as it can lead to pericardial effusion causing tamponade, often necessitating emergency pericardiocentesis and rarely, cardiac surgery. With increasing treatment of complex coronary lesions, such as chronic total occlusion (CTO), the incidence of coronary perforation is also increasing. Distal wire perforation and collateral vessel perforation can be managed by coil embolization during PCI, which prevented the need of cardiac surgery.

Purpose
To report the short and long-term outcomes of patients with coronary perforation as a complication of PCI managed by coil embolization in our center

Methods
We retrospectively analyzed 66 patients who had coronary perforation treated by coil embolization during PCI from 32007 PCI procedures performed in our center from Oct 2012 to June 2018.

Results
Of sixty-six cases of coronary perforation, twenty-six cases were distal coronary perforation, while 40 cases were collateral perforation. The average coil number used in distal coronary and collateral perforation lesion is 1.8±0.9 and 1.8±1.0, respectively. The maximum number of coil implanted in each patient is 4 in both groups. Two emergency cardiac surgery to seal the perforation was performed after coil embolization in distal coronary perforation and pericardiocentesis, including one distal left circumflex artery perforation and one distal left anterior descending artery perforation. In collateral perforation, one case of CABG was performed due to myocardial ischemia caused by CTO lesion. During a follow-up of 707±476 days, one patient in collateral perforation group had CABG one month later, while no death or myocardial infarction (MI) was detected. Fifty-four (81.2%) cases of perforations occurred while treating chronic total occlusion, and 74.0% of these perforations were located in collateral vessels, mostly epicardial vessels. Thirty-nine CTO cases (72.2%) were revascularized successfully with the aid of coil embolization.

Conclusion
Coil embolization is feasible and effective in treating distal coronary perforation and collateral perforation during PCI procedure. In CTO lesions, coil embolization facilitates the success of revascularization by PCI.
P6530Clinical outcomes of dialysis patients treated with current generation DES for left main distal bifurcation
Authors: Watanabe Y , Mitomo S , Naganuma T , Nakajima A , Tani K , Matsuoka S , Kawamoto H , Tanaka K , Sato T , Ishiguro H , Okutsu M , Tahara S , Kurita N , Nakamura S H , Nakamura S 
Published: October 2019

Abstract

Objectives
We assessed clinical outcomes after percutaneous coronary intervention (PCI) for unprotected left main (ULM) using current generation drug eluting stents (cDES) in hemodialysis (HD) patients compared to general populations.

Methods
We identified 1269 consecutive patients who underwent PCI for ULM distal bifurcation lesions. Of them, 563 patients were treated with cDES (512 non HD and 51 HD patients). The primary endpoint was target lesion failure (TLF) at 3 years, defined as a composite of cardiac death, target lesion revascularization (TLR) and myocardial infarction (MI).

Results
HD group was more likely to have diabetes mellitus (70.0% vs. 45.8%, p=0.002), peripheral artery disease (56.0% vs. 14.9%, p<0.001), and lower ejection fraction (52.6% vs. 56.3%, p=0.026). The rate of TLF at 3 years was significantly higher in the HD group (adjusted Hazard ratio [HR] 2.59; 95% confidence interval [CI], 1.54–4.37; p<0.001). Cardiac mortality was significantly higher in the HD group (adjusted HR 4.49; 95% CI, 2.07–9.74; p<0.001). The rates of TLR for LM-left anterior descending artery (LAD) and left circumflex ostium (LCXos) were significantly higher in the HD group (LMT-LAD: adjusted HR 3.10; 95% CI, 1.31–7.33; p=0.01, LCXos: adjusted HR 2.56; 95% CI, 1.32–4.94; p=0.005). The rate of MI was similar between the 2 groups.

Conclusions
Hemodialysis was strongly associated with adverse events after PCI for ULM distal bifurcation lesions even with cDES.
P6544A real world study of high frequency atrial anti-tachycardia pacing in new algorithm for atrial arrhythmia
Authors: Fukunaga M , Morinaga T , Yamaji K , Nagashima M , Ando K 
Published: October 2019

Abstract

Background
Advanced pacemakers feature atrial antitachycardia pacing (aATP) therapies for terminating atrial arrhythmia. Previous studies showed the efficacy of combined atrial preventive pacing and aATP in patients with pacemakers. The independent effect of aATP and the impact for patients outside the clinical trials has not been well elucidated.

Methods
In a single center, prospective, all-comers trial, we enrolled 567 patients implanted cardiac devices with Reactive ATP function. History of permanent atrial fibrillation (AF) was not included. After device interrogation of the AF burden and the longest AF duration in the last 6 months, aATP was programmed as a bit more aggressive setting than MINERVA trial (time interval was set as every 2 hours). As for newly implanted devices, aATP was activated after at least 3 months run-in period. Primary and secondary outcomes were the longest AF duration and cumulative percentage of progression into permanent AF, respectively.

Results
Of 541 eligible patients, aged 75.3±10.7 years, 356 pacemaker, 82 ICD and 103 CRT patients, the longest single episode of AF lasted ≤6 min in 439 patients (81.1%), >6 min to 6 h in 43 (8.0%), >6–24 h in 33 (6.1%), and >24 h in 26 (4.8%) at the enrollment. During mean follow-up of 1.9 years, the longest AF episode lasted >24 h in 49 patients (9.1%) and 14 patients (2.6%) progressed into permanent AF. According with baseline longest single episode of AF, patients with AF ≤6 min developed an episode >24 h in 0.8% at 1 year and 3.2% at 2 years follow up; patients with AF >6 min to 6 h developed an episode >24 h in none at 1 year and 7% at 2 years follow up; and patients with AF >6–24 h developed an episode >24 h in 19% at 1 year and 42% at 2 years follow up, respectively. In a subgroup analysis of in 192 patients with at least 1 aATP, 46 patients with high efficacy (>44%) did not developed an episode >24 h. Only one patient developed into permanent AF without aATP therapy. On multivariate analysis, neither ICD nor CRT was independent risk factor for developing the longest AF episode >24 h.

Conclusions
The independent use of aATP without atrial preventive pacing was effective for preventing AF progression in a real world cohort. Even without the previous AF episodes, aATP could prevent AF development, especially in patients showing high aATP efficacy. Future research is required to enhance the aATP success rate.
P6554Utility of accelerometer programmation in leadless pacemaker regardind location. CARDIOCHUS registry
Authors: Martinez Sande J L , Garcia-Seara J , Gonzalez-Melchor L , Fernandez-Lopez X A , Rodriguez-Manero M , Lopez-Canoa J N , Alvarez-Rodriguez L , Romero-Roche L , Abou-Jokh-Casas C , Vidal-Perez R C , Gonzalez-Juanatey J R 
Published: October 2019

Abstract

Background
Real-world data reinforce positive results in different implant locations of leadless pacemaker (LPM). LPM have special characteristics regarding accelerometer programmation.

Purpose
The purpose of the study was to describe our experience with LPM different implantation location and its programmation according the vector accelerometer.

Methods
We performed a prospective observational one center study including all patients with LPM implantation within 3 years (June 2015-December 2018). Location of deployment was classified as apicalseptal, midseptal or right ventricle outflow tract (RVOT). Vector programmation was performed from the second visit in patients with acceptable mobility and heart rate below 80 bpm, with the abbreviated protocol recommended by the brand. Clinical evaluation according to vector programmed was performed 3 to 6 months later.

Results
We include a total of 144 LPM, and exercise test was performed in 86 patients. There were 86 men (59.7%) with a mean age of 79.1±6.9 years-old (54 to 89). Location of deployment was distributed as follows: 32.4% in apicalseptal, 54.5% in midseptal and 13.1% in RVOT. Vector 1 was the more frequent programmation, specially in apicalseptal position. Correlation between location and vector of programmation could not be predicted (p=0.2381), but there was a non-significant tendency (p=0.08) between patients with LPM in RVOT location and Vector 3 programmation. Table 1 and Figure 1.
Table 1. Micra Location and Activity Vector Apicalseptal Midseptal RVOT P Value Test Vector 39 (84.8%) 40 (58.5%) 7 (46.7%) NS Vector 1 22 (56.4%) 26 (65.0%) 2 (28.6%) NS Vector 2 8 (20.5%) 4 (10.0%) 1 (14.3%) NS Vector 3 9 (23.1%) 10 (25.0%) 4 (57.1%) 0.08
Figure 1

Conclusions
In our series, Vector 1 was the predominant accelerometer programmation specially in apicalseptal LPM position and Vector 3 in RVOT position.
P6555A self-adaptive approach to antitachycardia pacing - a head to head comparison using advanced computational modeling
Authors: Swenson D , Blauer J , Taepke R , Kwan E , Ghafoori E , Barton M , Tate J , Coles J , MacLeod R , Degroot P , Ranjan R 
Published: October 2019

Abstract

Background
Antitachycardia pacing (ATP) for monomorphic VT (MVT) reduces painful defibrillation shocks. Most ICD-treated ventricular arrhythmias are MVT, suggesting an opportunity for improved ATP to decrease shocks. We report on a new algorithm (Yee, Circ AE 2017) that uses electrophysiologic (EP) first-principles to design ATP sequences in real-time. Heart-rate history is used to design the first ATP sequence, and failed ATP post-pacing interval is used to design later sequences.

Purpose
The purpose of this modeling study was to understand how this new ATP algorithm would perform in a head-to-head comparison with traditional burst ATP. Modeling allows direct comparison of the two algorithms in identical, realistic, patient-derived cardiac arrythmias.

Methods
Patient-specific late gadolinium enhanced MRI and EP data were used to build an adjudicated cohort of realistic numerical heart models with varied EP, infarct, border zone. Publicly available EP modeling software CARPentry was used to calculate sustained reentrant VT initiated with the programmed electrical stimulation used to induce VT clinically. The VTs were physician-adjudicated to validate models. Burst ATP was 3 sequences of 8 pulses at 88% of VT cycle length, each decremented by 10ms. The new ATP was limited to 3 automatically designed sequences.

Results
Three hundred unique VT scenarios were generated from 6 human hearts with multiple VT circuits, 5 electrophysiologic states, and 10 pacing locations. Burst ATP terminated 168/300 VTs (56%) and accelerated 2.7%. The new ATP terminated 234/300 VTs (78%) with the same acceleration. The two dominant ATP failure mechanisms were identified as 1) insufficient prematurity to close the excitable gap, and 2) failure to reach the critical isthmus of the VT circuit. For these mechanisms, the new ATP algorithm reduce failures from 64 to 28 (44% reduction) without increasing acceleration.

Conclusion
The new automated ATP algorithm successfully adapted ATP sequences for VT episodes that burst ATP failed to terminate. The new ATP was successful even with complex scar geometries and electrophysiology heterogeneity as seen in the real world.
P6565The relation between the variation of CL and atrial tachycardia
Authors: Takigawa M T , Andre C A , Lam A L , Escande W E , Nakatani Y N , Zeng L Z , Duchateau J D , Pambrun T P , Denis A D , Hocini M H , Sacher F S , Jais P J , Haissaguerre M H , Derval N D 
Published: October 2019

Abstract

Background
Complex ATs with a complicated circuit have been increasing because of the native or iatrogenic scars in atrium. However, development of resolution in the EAM allows us to reach the correct diagnosis. The purpose of this study was to reassess the relationship between characteristics of ATs and cycle length based on the correct diagnosis with high-resolution mapping system.

Method
Among 85 consecutive AT patients treated with with high-resolution mapping system “Rhythmia”, patients with at least one mappable AT during procedure were prospectively included in this study. Maximal, minimal, and variation of ATCL was calculated from the decapolar in the coronary sinus (CS) during 2minutes, and the relation between CL and respiration was measured on the Rhythmia (Figure 1). These values were compared to AT types.

Results
90 ATs in 65 patients (mean 59±13 yrs, 16 females, 55 post-AF ATs) including 4 focal-ATs, 23 localized-AT, and 63 macroreentrant ATs were analyzed. As shown in the table 1, the maximum and minimum CL was similar between focal-AT, localized-AT, and, macroreentrant-AT. However, both absolute CL-variation and ratio of CL-variation were significantly smaller in macroreentrant ATs (P=0.009 and P=0.0012, respectively). Table 2 described the comparison between 66 left-ATs and 24 right-ATs. Although the maximum and minimum CL were similar, both absolute CL-variation and ratio of CL-variation were significantly larger in right ATs (P=0.001 and P=0.007, respectively). Additionally, the correlation of CL to the respiration was significantly more frequently seen in the right-ATs (3.0% in left-ATs and 62.5% in right-ATs, P<0.0001).
Table 1, 2 and Figure 1

Conclusions
CL-variation of ATs may be significantly smaller in macroreentrant ATs and significantly larger in right ATs. CL-variation correlated to the respiration may suggest right-ATs. These information may be helpful to diagnose ATs before mapping.